Micro-organism Destroying Or Inhibiting Patents (Class 514/2.3)
  • Patent number: 11219603
    Abstract: The invention relates to the field of medicine and pharmaceuticals and particularly to a novel dosage form of an antitumor preparation, which ensures the hydrolytic and physical stability of said preparation, as well as to a method for producing a dosage form of this type. The stable dosage form is a lyophilizate comprising an etidronate-cytarabine conjugate or a pharmaceutically acceptable salt thereof, and a stabilizer, which is a divalent metal salt, in a molar ratio of stabilizer to conjugate of 1:1 to 20:1. A dosage form of this type ensures the hydrolytic and physical stability of the conjugate during long-term storage, and the stability of solutions of the conjugate for parenteral administration during clinical use.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: January 11, 2022
    Assignee: MAXWELL BIOTECH GROUP LTD.
    Inventors: Ekaterina Alekseevna Ivanova, Alexander Karpeisky, Shawn P. Zinnen, Lisa Lynn Caralli, Rina Diana Fong
  • Patent number: 11161883
    Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to polypeptides comprising the sequence of a peptidoglycan hydrolase and a peptide sequence heterologous to the peptidoglycan hydrolase wherein said heterologous peptide sequence comprises a specific sequence motif which is 16, 17, 18, 19 or 20 amino acids in length. The present invention relates also to corresponding nucleic acids, vectors, bacteriophages, host cells, compositions and kits. The present inventions also relates to the use of said polypeptides, nucleic acids, vectors, bacteriophages, host cells, compositions and kits in methods for treatment of the human or animal body by surgery or therapy or in diagnostic methods practiced on the human or animal body. The polypeptides, nucleic acids, vectors, bacteriophages, host cells, compositions and kits according to the invention may also be used as an antimicrobial in, e.g., food or feed, in cosmetics, or as disinfecting agent.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: November 2, 2021
    Assignee: SASINAPAS CO., LTD
    Inventor: Martin Griessl
  • Patent number: 11061037
    Abstract: Disclosed herein is a method for classifying a patient at risk for heart failure, wherein the method comprises the steps of (i) measuring the concentration of IGFBP2 in a sample obtained from the patient and (ii) comparing the concentration of IGFBP2 measured in step (i) to a control value derived from the concentration of IGFBP2 in samples from patients who are at particular stages of heart failure and/or to a control value derived from the concentration of IGFBP2 in blood samples from healthy patients.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: July 13, 2021
    Assignees: INSERM (INSTITUT DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
    Inventors: Philippe Rouet, Fatima Smih-Rouet, Franck Desmoulin, Michel Galinier
  • Patent number: 10959947
    Abstract: The invention relates to stable vancomycin hydrochloride powder for oral liquid formulations. Also provided herein are methods of using vancomycin oral liquid formulations for the treatment of certain diseases such as Clostridium difficile pseudomembranous colitis and Staphylococcal enterocolitis as well as kits and related products thereof.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: March 30, 2021
    Assignee: Azurity Pharmaceuticals, Inc.
    Inventors: Indu Muni, Peter Mione, Anisa Gandhi, Cristina LeChiara
  • Patent number: 10959946
    Abstract: The invention relates to stable vancomycin hydrochloride powder for oral liquid formulations. Also provided herein are methods of using vancomycin oral liquid formulations for the treatment of certain diseases such as Clostridium difficile pseudomembranous colitis and Staphylococcal enterocolitis as well as kits and related products thereof.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: March 30, 2021
    Assignee: Azurity Pharmaceuticals, Inc.
    Inventors: Indu Muni, Peter Mione, Anisa Gandhi, Cristina LeChiara
  • Patent number: 10927147
    Abstract: The invention relates to novel Muramyl Dipeptide (MDP) derivative compound of structural Formula-VIII, a process for synthesis, intermediates used in the synthesis and use thereof. Wherein, R can be both linear and branched alkyl, aryl, substituted aryl and alkoxy alkyl. These compounds possess excellent pharmacological properties, in particular immunomodulating properties for use as adjuvant in vaccine formulations. These compounds are, particularly useful as adjuvants in vaccines.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: February 23, 2021
    Assignees: Bharat Biotech International Limited, Council of Scientific and Industrial Research
    Inventors: Krishna Murthy Ella, Ganneru Brunda, Halmathur Mahabalarao Sampath Kumar, Miryala Sreekanth
  • Patent number: 10765720
    Abstract: A composition for alleviating, preventing, or treating hyperoxia-induced lung injury, the composition including the WKYMVm peptide as an active ingredient is described. The composition has an effect of increasing FPR2 activation and ERK phosphorylation, and also has an effect of improving alveolarization and angiogenesis in hyperoxia-induced lung injury models, and thus the composition is anticipated to be usefully used for the alleviation, prevention, or treatment of hyperoxia-induced lung injury, particularly bronchopulmonary dysplasia.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: September 8, 2020
    Assignees: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION
    Inventors: Yun Sil Chang, Won Soon Park, So Yoon Ahn, Dong Kyung Sung, Young Eun Kim, Jae Ho Kim
  • Patent number: 10588954
    Abstract: Described herein are multilayer films that include modified polypeptide epitopes from Plasmodium falciparum, specifically a modified T* epitope. The multilayer films are capable of eliciting an immune response in a host upon administration to the host. The multilayer films can include at least one designed peptide that includes the modified T* polypeptide epitope from a Plasmodium protozoan.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: March 17, 2020
    Assignee: ARTIFICIAL CELL TECHNOLOGIES, INC.
    Inventors: James Gorham Boyd, Thomas J. Powell
  • Patent number: 10543250
    Abstract: Antimicrobial peptides, compositions and methods are described that are useful for treating infectious diseases, including those caused by drug resistant Gram-negative bacteria (e.g., Pseudomonas and Acinetobacter) and parasite-caused diseases such as malaria. The peptides include a modular kinocidin gamma-core connected directly, or through a short spacer, to a kinocidin C-terminal alpha-helix.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: January 28, 2020
    Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventor: Michael R. Yeaman
  • Patent number: 10520504
    Abstract: A probe for detecting bacteria and/or fungi in vitro and in vivo is provided, the probe having a core and a plurality of probe elements; each probe element within the plurality of probe elements extending from the core and having a fluorophore and a binding moiety, wherein the binding moiety is a bacteria binding moiety and selectively binds to bacteria and/or to fungi and not to animal cells. Methods of use of the probe and kits comprising the probe are also provided.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: December 31, 2019
    Assignee: The University Court of the University of Edinburgh
    Inventors: Mark Bradley, Annamaria Helena Lilienkampf, Nikolaos Avlonitis, Marc Vendrell Escobar, Neil Alexander McDonald, Christopher Haslett, Kanwaldeep Dhaliwal, Timothy Simon Walsh
  • Patent number: 10092643
    Abstract: Provided is use of a sphingosine compound, or a derivative of a sphingosine compound, in the manufacture of a vaccine effective in the treatment and prevention of an infectious disease and treatment and/or prevention of an autoimmune disease. Also provided is use of a sphingosine compound, or a derivative of a sphingosine compound, in the manufacture of an immunomodulation medicament effective in the prevention of infectious disease and treatment and/or prevention of an autoimmune disease.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: October 9, 2018
    Inventor: Marc Creus
  • Patent number: 10000577
    Abstract: A method of treating otitis media in a subject is described that includes administering to the subject a therapeutically effective amount of an Actin-Related Protein 2/3 Complex (Arp2/3) inhibitor. The role of Arp2/3 in otitis media was identified using comprehensive proteomic and metabolomic studies of otitis media using the chinchilla model.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: June 19, 2018
    Assignee: Research Institute At Nationwide Children's Hospital
    Inventors: Sheryl S. Justice, Kevin M. Mason, Alistair Harrison
  • Patent number: 9872885
    Abstract: Antimicrobial and/or anti-inflammatory peptide compositions and therapeutic uses thereof are provided. The peptides and analogs or derivatives thereof may be used as an antimicrobial agent and/or as an anti-inflammatory agent. In certain embodiments, the peptides are cationic peptides. The peptides are useful for the treatment of inflammatory diseases, such as microorganism-caused infections, acne, and psoriasis. The peptides and peptide formulations may be used topically or parenterally.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: January 23, 2018
    Assignee: CARRUS CAPITAL CORPORATION
    Inventors: Patricia J. McNicol, Sonia K. Pawlak, Evelina Rubinchik, Dale Cameron, Maria Marta Guarna, Janet R. Fraser, Shafique Fidai, Yuchen Chen, Timothy J. Krieger
  • Patent number: 9801861
    Abstract: Disclosed are compositions having activity against MRSA and/or VRSA, and methods of using the compositions to treat microbial infections.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: October 31, 2017
    Assignee: Purdue Research Foundation
    Inventors: Mark Stanley Cushman, Mohamed Seleem, Abdelrahman S Mayhoub
  • Patent number: 9676711
    Abstract: The present invention relates to novel sulfoperoxycarboxylic acid compounds, and methods for making and using them. The sulfoperoxycarboxylic compounds of the invention are storage stable, water soluble and have low to no odor. Further, the compounds of the present invention can be formed from non-petroleum based renewable materials. The compounds of the present invention can be used as antimicrobials, and bleaching agents. The compounds of the present invention are also suitable for use as coupling agents.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: June 13, 2017
    Assignee: Ecolab USA Inc.
    Inventors: Li Junzhong, Richard Staub, David D. McSherry, Keith G. Lascotte, Steven J. Lange, Frank Everts
  • Patent number: 9588125
    Abstract: A peptide is cleaved at various bonding sites into oligopeptides or similar fragments by digestion using proteinase K (S3). The obtained fragments are separated according to their kinds by reversed-phase chromatography and fractionated (S4), and each fragment is subjected to mass spectrometry to determine its mass (S6). For each peptide fragment, an amino-acid composition is calculated from the measured mass, and amino-acid sequence candidates are deduced from that composition. The amino-acid sequence candidates of the other peptide fragments are searched for a fragment having an overlapping portion available for combining two peptide fragments to obtain amino-acid sequence candidates of the original peptide (S7). The masses of the amino-acid sequence candidates are compared with a measured mass derived from a result of mass spectrometry of the original peptide to select a correct sequence (S6 and S8).
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 7, 2017
    Assignee: SHIMADZU CORPORATION
    Inventors: Akiyasu Yoshizawa, Takayuki Yoshimori, Yuki Ohta
  • Patent number: 9167816
    Abstract: The invention relates to a method of controlling or combating microbial organism by applying an antimicrobial peptide to the microbial organisms, wherein said antimicrobial peptide derived from Lilium ‘Stargazer’ glycine-rich protein 1. In addition, the present invention provides an antimicrobial composition comprising an antimicrobial peptide of the invention, an additional biocidal agent and pharmaceutically acceptable vehicles, excipients, diluents, and adjuvants.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: October 27, 2015
    Assignee: NATIONAL TAIWAN UNIVERSITY
    Inventors: Chao-Ying Chen, Chia-Hua Lin, Min-Wei Chang
  • Patent number: 9133257
    Abstract: The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: September 15, 2015
    Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: Michael R. Yeaman, Alexander J. Shen
  • Publication number: 20150148285
    Abstract: The present invention provides an antimicrobial peptide, wherein the amino terminal and/or carboxyl terminal of the peptide is linked with at least one artificial bulkyl amino acid to increase the salt resistance and protease resistance of the antimicrobial peptide. The antimicrobial peptide of the invention has a high salt resistance, a high protease resistance, and a low hemolytic activity, simultaneously.
    Type: Application
    Filed: May 8, 2014
    Publication date: May 28, 2015
    Applicant: National Tsing Hua University
    Inventors: Jya-Wei Cheng, Hui-Yuan Yu, His-Tsung Cheng
  • Publication number: 20150141324
    Abstract: It is provided furin inhibitors and their uses for treating pathogen infection. Particularly, it is provided a method or use for the treatment of a pathogen infection, in a subject, comprising administering to the subject a therapeutically effective amount of the furin inhibitors or the composition disclosed, thereby preventing or treating pathogen infection, in the subject.
    Type: Application
    Filed: August 31, 2012
    Publication date: May 21, 2015
    Applicant: SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.
    Inventors: Robert Day, Witold A. Neugebauer, Yves Dory
  • Publication number: 20150141323
    Abstract: The present description provides compositions and methods for producing therapeutic oligomeric compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof.
    Type: Application
    Filed: August 21, 2014
    Publication date: May 21, 2015
    Inventors: Gilles Guichard, Robert Zimmer, Juliette Fremaux
  • Publication number: 20150132220
    Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.
    Type: Application
    Filed: January 8, 2015
    Publication date: May 14, 2015
    Inventors: Philip E. Thorpe, Jin He
  • Publication number: 20150104492
    Abstract: The present invention provides synthetic antibacterial peptides comprising a sequence at least 80% identical to a sequence shown in SEQ ID NO: 2 or the diastereomer thereof with a sequence shown in SEQ ID NO: 3 or pharmaceutical compositions thereof. Also provided are methods for reducing the severity of microbe-induced inflammation and for stimulating wound healing via the synthetic antibacterial peptides. Further provided is a device having a surface with a coating comprising the synthetic antibacterial peptides.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 16, 2015
    Inventors: Alison McDermott, Marialuisa Mangoni
  • Patent number: 9006174
    Abstract: The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wild-type CMAP27 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Further comprised in the invention is the use of CMAP27 and/or its derivatives as adjuvant.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: April 14, 2015
    Assignee: Universiteit Utrecht Holding B.V.
    Inventors: Floris Jacob Bikker, Albert Van Dijk, Rosalia Mars-Groenendijk, Edwin Johannes Adrianus Veldhuizen, Desiree Van Der Kleij, Hendrik Haagsman, Elisabeth Margaretha Molhoek
  • Publication number: 20150094256
    Abstract: Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.
    Type: Application
    Filed: December 11, 2014
    Publication date: April 2, 2015
    Inventors: Mona Ståhle-Bäckdahl, Johan Heilborn, Anders Carlsson, Conny Bogentoft
  • Publication number: 20150094255
    Abstract: The invention provides, inter alia, conjugates of a hydratable polymer (such as PEG, polyethylene glycol) and a lectin (such as wheat germ agglutinin, WGA), compositions comprising these conjugates, as well as methods and targeted uses of these conjugates and compositions for, e.g., lubricating, maintaining hydration of rehydrating, and/or inhibiting microorganism colonization of a biological surface in need thereof.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 2, 2015
    Inventors: Katharina Ribbeck, Thomas Crouzier
  • Publication number: 20150086604
    Abstract: Biodegradable polymer-coated surgical meshes formed into pouches are described for use with cardiac rhythm management devices (CRMs) and other implantable medical devices. Such meshes are formed into a receptacle, e.g., a pouch or other covering, capable of encasing, surrounding and/or holding the cardiac rhythm management device or other implantable medical device for the purpose of securing it in position, inhibiting or reducing bacterial growth, providing pain relief and/or inhibiting scarring or fibrosis on or around the CRM or other implantable medical device. Preferred embodiments include surgical mesh pouches coated with one or more biodegradable polymers that can act as a stiffening agent by coating the filaments or fibers of the mesh to temporarily immobilize the contact points of those filaments or fibers and/or by increasing the stiffness of the mesh by at least 1.1 times its original stiffness.
    Type: Application
    Filed: September 23, 2013
    Publication date: March 26, 2015
    Inventors: Fatima Buevich, Frank Do, William McJames, Satish Pulapura, William Edelman, Arikha Moses, Mason Diamond, Shari Timothy
  • Publication number: 20150080290
    Abstract: Compositions comprising a mixture of an antimicrobial cationic polypeptide and a second pharmaceutically-acceptable polymer are disclosed, as well as methods and uses thereof for the treatment and prevention of infections that occur when our natural barriers of defense are broken.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 19, 2015
    Inventors: Michael P. Bevilacqua, Diego Benitez, Jarrod A. Hanson
  • Publication number: 20150080292
    Abstract: This invention provides new cyclic lipopeptide antibiotic Locillomycin (Locillomycin-A, Locillomycin-B, Locillomycin-C) that display very strong antifungal, antibacterial, antivirus activities in a variety of contexts in vitro; methods of making and using the compounds, wherein Locillomycin-A, Locillomycin-B and Locillomycin-C are derived and purified from the culture of Bacillus subtilis Bs916.
    Type: Application
    Filed: February 26, 2014
    Publication date: March 19, 2015
    Inventor: Chuping Luo
  • Publication number: 20150072922
    Abstract: Described herein are compounds and compositions comprising antimicrobial peptides and methods for their use.
    Type: Application
    Filed: April 17, 2013
    Publication date: March 12, 2015
    Inventors: David Hains, Andrew Schwaderer, Huanyu Wang
  • Patent number: 8969290
    Abstract: The invention provides a scaffold of extracellular matrix polymers with recombinant chimeric peptides tethered thereto. The invention also provides recombinant chimeric peptides of antimicrobial peptides and extracellular matrix binding domains. The invention also provides methods for treating chronic wounds using the scaffold and/or recombinant chimeric peptides.
    Type: Grant
    Filed: June 26, 2013
    Date of Patent: March 3, 2015
    Assignee: Worcester Polytechnic Institute
    Inventors: Marsha Rolle, Fioleda Prifti, Chris Malcuit, Terri Anne Camesano, Tanja Dominko, Denis Kole
  • Patent number: 8961873
    Abstract: The present invention describes a new system and method, named “Antinfection”, to protect primarily healthcare workers (HCWs) and patients against communicable and nosocomial infections. It's based on new antiseptic sprays, non-alcoholic, that can be sprayed automatically on the hands. The base of the antiseptic action is the persistent part, preventing the colonization of tissue and non-living surfaces with microorganisms through the targeted, on-demand release of Fluorine ions. The system including new sprayers for fast and controlled application; new technologies to secure the long-term protection against wear in the daily work routines of HCWs; new measurement techniques for the quality of the Antinfection; new quality recording concepts for the promotion and verification of new strategies and campaigns in the “lost war against the germs”.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: February 24, 2015
    Inventors: Fridolin Voegeli, Ghanem E. Ghanem
  • Publication number: 20150045287
    Abstract: The invention relates to a method of controlling or combating microbial organism by applying an antimicrobial peptide to the microbial organisms, wherein said antimicrobial peptide derived from Lilium ‘Stargazer’ glycine-rich protein 1. In addition, the present invention provides an antimicrobial composition comprising an antimicrobial peptide of the invention, an additional biocidal agent and pharmaceutically acceptable vehicles, excipients, diluents, and adjuvants.
    Type: Application
    Filed: August 9, 2013
    Publication date: February 12, 2015
    Applicant: National Taiwan University
    Inventors: Chao-Ying CHEN, Chia-Hua LIN, Min-Wei CHANG
  • Patent number: 8951958
    Abstract: The present invention relates to a method for the purification of cyclopeptides of general formula (3) by means of a silicate.
    Type: Grant
    Filed: March 22, 2011
    Date of Patent: February 10, 2015
    Assignee: DSM Sinochem Pharmaceuticals Netherlands B.V.
    Inventor: Robertus Mattheus De Pater
  • Publication number: 20150038406
    Abstract: The present invention relates to pharmaceutical formulations comprising tranexamic acid, kits thereof, and methods for treating bleeding by local administration.
    Type: Application
    Filed: July 8, 2014
    Publication date: February 5, 2015
    Inventors: Matthew James Buderer, Jeffrey Joel Abrams
  • Publication number: 20150038407
    Abstract: The present invention relates to novel agents, pharmaceutical compositions containing them, and theft use in therapy, particularly anti-microbial and anti-cancer therapy. In particular, the present invention relates to novel peptide-based compounds based on SEQ ID NO: 40 which have surprisingly been shown to have inhibitory effects on the growth and/or viability of cells, particularly bacterial and cancer cells. Also provided are therapeutic and non-therapeutic methods which include the use of peptides of the invention.
    Type: Application
    Filed: June 16, 2014
    Publication date: February 5, 2015
    Inventor: Lars Prestegarden
  • Publication number: 20150031600
    Abstract: The present invention relates to designed polypeptide biosurfactants that may be prepared by recombinant technology in commercially useful amounts and purified by simple non-chromatographic methods. The designed polypeptide biosurfactants comprise at least one stimuli-responsive amino acid residue or at least one glutamine or asparagine residue and may be useful in modulating the stability of a foam, alone or in combination with an ?-helical peptide. The designed polypeptide biosurfactant may be useful in the formation and collapse of foams in foods, beverages, pharmaceuticals, personal care products, cosmetics, cleaning products, mineral recovery, bioremediation, oil recovery and laundry products. The designed biosurfactants may also be useful in recombinant production and purification of peptides, polypeptides and proteins.
    Type: Application
    Filed: December 14, 2011
    Publication date: January 29, 2015
    Applicant: The University of Queensland
    Inventors: Anton Peter Jacob Middelberg, Mirjana Dimitrijev-Dwyer, Michael Brech
  • Publication number: 20150030566
    Abstract: Compositions containing one or more tyrocidines, tryptocidines, phenycidines and/or gramicidin S, or derivatives and analogues thereof, are described for controlling antimicrobial growth on plants, plant material or plant growth media, and methods for controlling or preventing the growth of microbial pathogens, and in particular fungal pathogens, on plants, plant parts and plant material are described herein. The active agents used to control these pathogens are tyrocidines, tryptocidines, phenycidines and/or gramicidin S, or derivatives, analogues or modifications thereof.
    Type: Application
    Filed: August 22, 2013
    Publication date: January 29, 2015
    Inventors: Marina Rautenbach, Abré De Beer, Anscha Mari Troskie, Johan Arnold Vosloo
  • Publication number: 20150031601
    Abstract: The present invention relates to variants of a parent antimicrobial peptide. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: August 11, 2014
    Publication date: January 29, 2015
    Applicant: ADDENIUM BIOTECH APS
    Inventors: Hans-Henrik Kristensen Hoegenhaug, Per Holse Mygind, Thomas Kruse, Dorotea Raventos Segura, Dorthe Hoj Sandvang, Soren Neve
  • Patent number: 8940687
    Abstract: Antimicrobial compositions based upon stabilized angiogenin compositions also contain osteopontin and antimicrobial proteins such as lactoperoxidase (LPO), myeloperoxidase (MPO), salivary peroxidase (SPO) and lysozyme.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: January 27, 2015
    Assignee: Naidu LP
    Inventors: A. Satyanarayan Naidu, A. G. Tezus Naidu, A. G. Sreus Naidu
  • Publication number: 20150023912
    Abstract: The present invention relates to a composition comprising at least two different albumin-based drug delivery systems, as well as to a pharmaceutical composition comprising said composition.
    Type: Application
    Filed: February 21, 2013
    Publication date: January 22, 2015
    Inventors: Felix Kratz, Andre Warnecke
  • Patent number: 8937155
    Abstract: The present invention relates to a antimicrobial peptide or peptide derivative comprising the following sequence: Sub1-X1-D2-K3-P4-P5-Y6-L7-P8-R9-P10-X2-P12-P13-R14-X3-T16-P17-N18-N19-X4-Sub2. The invention further relates to multimers comprising said peptides or peptide derivatives. Moreover, the invention provides a peptide or peptide derivative for use in the treatment of a disease. The peptide or peptide derivative may also be used in the screening for novel antimicrobial compounds.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: January 20, 2015
    Assignee: AMP Therapeutics GmbH
    Inventors: Ralf Hoffmann, Daniel Knappe
  • Patent number: 8936782
    Abstract: The present invention describes method of treating bacterial infections, including MRSA. In various embodiments, the methods can use interferon beta, which is found to have antimicrobial activity. In certain embodiments, the interferon beta can be human interferon beta. In other embodiments, the interferon beta can be mouse interferon beta. In further embodiments, the interferon beta can be human interferon beta containing amino acid substitutions to make the human interferon beta more cationic in neutral pH.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: January 20, 2015
    Assignee: Cedars-Sinai Medical Center
    Inventors: David M. Underhill, George Y. Liu, Amber Kaplan
  • Patent number: 8933029
    Abstract: Antimicrobial and/or anti-inflammatory peptide compositions and therapeutic uses thereof are provided. The peptides and analogs or derivatives thereof may be used as an antimicrobial agent and/or as an anti-inflammatory agent. In certain embodiments, the peptides are cationic peptides. The peptides are useful for the treatment of inflammatory diseases, such as microorganism-caused infections, acne, and psoriasis. The peptides and peptide formulations may be used topically or parenterally.
    Type: Grant
    Filed: August 26, 2002
    Date of Patent: January 13, 2015
    Assignee: Carrus Capital Corporation
    Inventors: Patricia J. McNicol, Sonia K. Pawlak, Evelina Rubinchik, Dale Cameron, Maria Marta Guarna, Janet R. Fraser, Shafique Fidai, Yuchen Chen, Timothy J. Krieger
  • Patent number: 8933016
    Abstract: It is an object of the present invention to provide antimicrobial metallodrugs comprising an antimicrobial peptide (“AMP”) and/or an antibiotic covalently bound to a metal binding moiety. These metallodrugs combine a metal binding domain which typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, with a member of a diverse class of antimicrobial agents currently validated in preclinical and clinical settings for the treatment of a broad spectrum of pathogenic organisms.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: January 13, 2015
    Assignee: MetalloPharm, LLC
    Inventors: James A. Cowan, Ada S. Cowan
  • Publication number: 20150011465
    Abstract: Novel peptoid oligomers are disclosed that have a formula represented by the following formula I: The peptoids demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present cyclic and linear peptoids are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics.
    Type: Application
    Filed: September 9, 2014
    Publication date: January 8, 2015
    Inventors: Kent Kirshenbaum, Sung Bin Shin
  • Publication number: 20150010509
    Abstract: Disclosed herein are methods for the treatment of cancer and inflammatory-based diseases and disorders, such as hepatitis B virus infection, tuberculosis and type 2 diabetes based upon the administration of CaFolate. In one embodiment is a method of treating cancer comprising administration of CaFolate. In another embodiment is a method of treatment inflammatory-based disease and disorders comprising administration of CaFolate.
    Type: Application
    Filed: January 29, 2013
    Publication date: January 8, 2015
    Applicant: SanRx Pharmaceuticals, Inc.
    Inventor: Phillip Moheno
  • Publication number: 20140377289
    Abstract: It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a “ligand moiety”) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a “metallodrug” or “metallotherapeutic.” The metal binding domain of metallodrugs typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target.
    Type: Application
    Filed: September 9, 2014
    Publication date: December 25, 2014
    Inventors: James A. Cowan, Ada S. Cowan, Donna T. Palmer
  • Patent number: 8916516
    Abstract: The present invention relates to the use of a polypeptides, comprising repeats of a peptide derived from a Heparan Sulphate Proteoglycan (HSPG) receptor binding region of an apolipoprotein, for treating or preventing a fungal and/or protist infection. The invention further relates to the use of such peptides for treating or preventing the contamination of surfaces or objects with such peptides.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: December 23, 2014
    Assignee: AI2 Limited
    Inventor: Curtis Dobson
  • Patent number: 8906866
    Abstract: Provided herein are novel compounds and novel protected compounds that can be derived from polymyxin, including, e.g., polymyxin A. The novel compounds have antibacterial properties against a diverse range of Gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin A. Also provided are antibacterial pharmaceutical compositions containing the novel compounds and novel protected compounds, as well as methods for preparing the antibacterial compounds and protected compounds.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 9, 2014
    Assignees: BioSource Pharm, Inc., Cubist Pharmaceuticals, Inc.
    Inventors: William V. Curran, Christopher M. Liu, Amy C. D. Bombardier, Richard A. Leese, You Seok Hwang, Blaise S. Lippa, Yanzhi Zhang